NCT03093688View on ClinicalTrials.gov

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Non-small Cell Lung CancerSmall Cell Lung CancerPancreas CancerHepatocellular CarcinomaGastric CancerRenal Cell Carcinoma
Interventions
BIOLOGICAL

Infusion of iNKT cells and CD8+T cells

The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.

Trial Locations (1)

201508

RECRUITING

Shanghai Public Health Clinical Center, Shanghai

All Listed Sponsors
lead

Shanghai Public Health Clinical Center

OTHER_GOV